467 results on '"Devidas M"'
Search Results
2. Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia
- Author
-
Karol, SE, Larsen, E, Cheng, C, Cao, X, Yang, W, Ramsey, LB, Fernandez, CA, McCorkle, JR, Paugh, SW, Autry, RJ, Lopez-Lopez, E, Diouf, B, Jeha, S, Pui, C-H, Raetz, EA, Winick, NJ, Carroll, WL, Hunger, SP, Loh, ML, Devidas, M, Evans, WE, Yang, JJ, and Relling, MV
- Subjects
Patient Safety ,Cancer ,Pediatric Cancer ,Pediatric ,Childhood Leukemia ,Clinical Research ,Genetics ,Hematology ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Biomarkers ,Tumor ,Female ,Follow-Up Studies ,Genetic Predisposition to Disease ,Genotype ,Humans ,Male ,Neoplasm Recurrence ,Local ,Neoplasm Staging ,Polymorphism ,Single Nucleotide ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Risk Factors ,Clinical Sciences ,Oncology and Carcinogenesis ,Immunology - Abstract
The causes of individual relapses in children with acute lymphoblastic leukemia (ALL) remain incompletely understood. We evaluated the contribution of germline genetic factors to relapse in 2225 children treated on Children's Oncology Group trial AALL0232. We identified 302 germline single-nucleotide polymorphisms (SNPs) associated with relapse after adjusting for treatment and ancestry and 715 additional SNPs associated with relapse in an ancestry-specific manner. We tested for replication of these relapse-associated SNPs in external data sets of antileukemic drug pharmacokinetics and pharmacodynamics and an independent clinical cohort. 224 SNPs were associated with rapid drug clearance or drug resistance, and 32 were replicated in the independent cohort. The adverse risk associated with black and Hispanic ancestries was attenuated by addition of the 4 SNPs most strongly associated with relapse in these populations (for blacks: model without SNPs hazard ratio (HR)=2.32, P=2.27 × 10-4, model with SNPs HR=1.07, P=0.79; for Hispanics: model without SNPs HR=1.7, P=8.23 × 10-5, model with SNPs HR=1.31, P=0.065). Relapse SNPs associated with asparaginase resistance or allergy were overrepresented among SNPs associated with relapse in the more asparaginase intensive treatment arm (20/54 in Capizzi-methorexate arm vs 8/54 in high-dose methotrexate arm, P=0.015). Inherited genetic variation contributes to race-specific and treatment-specific relapse risk.
- Published
- 2017
3. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A Children's Oncology Group Study
- Author
-
Loh, Mignon, Matlawska-Wasowska, K, Kang, H, Devidas, M, Wen, J, Harvey, RC, Nickl, CK, Ness, SA, Rusch, M, Li, Y, and Onozawa, M
- Published
- 2016
4. Pusa HQPM-5 Improved
- Author
-
Hossain, F., Muthusamy, V., Gupta, H. S., Zunjare, R. U., Bhat, J. S., Nepolean, T., Mallikarjuna, M. G., Mukri, G., Kaul, J., Gadag, R. N., Saha, S., Manjaiah, K. M., Basu, S., Jha, Sunil K., Gogoi, R., Pooniya, V., Parihar, C. M., Kapasia, M., Kumar, R., Pal, D., Bhavi, B. G., Devidas, M., Dass, S., Dhanju, K. S., Pal, D., Mehla, J.C., Singh, D.P., and Kamboj, M. C.
- Published
- 2022
5. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
- Author
-
Hunger, S, Tran, T, Saha, V, Devidas, M, Valsecchi, M, Gastier-Foster, J, Cazzaniga, G, Reshmi, S, Borowitz, M, Moorman, A, Heerema, N, Carroll, A, Martin-Regueira, P, Loh, M, Raetz, E, Schultz, K, Slayton, W, Cario, G, Schrappe, M, Silverman, L, Biondi, A, Hunger S. P., Tran T. H., Saha V., Devidas M., Valsecchi M. G., Gastier-Foster J. M., Cazzaniga G., Reshmi S. C., Borowitz M. J., Moorman A. V., Heerema N. A., Carroll A. J., Martin-Regueira P., Loh M. L., Raetz E. A., Schultz K. R., Slayton W. B., Cario G., Schrappe M., Silverman L. B., Biondi A., Hunger, S, Tran, T, Saha, V, Devidas, M, Valsecchi, M, Gastier-Foster, J, Cazzaniga, G, Reshmi, S, Borowitz, M, Moorman, A, Heerema, N, Carroll, A, Martin-Regueira, P, Loh, M, Raetz, E, Schultz, K, Slayton, W, Cario, G, Schrappe, M, Silverman, L, Biondi, A, Hunger S. P., Tran T. H., Saha V., Devidas M., Valsecchi M. G., Gastier-Foster J. M., Cazzaniga G., Reshmi S. C., Borowitz M. J., Moorman A. V., Heerema N. A., Carroll A. J., Martin-Regueira P., Loh M. L., Raetz E. A., Schultz K. R., Slayton W. B., Cario G., Schrappe M., Silverman L. B., and Biondi A.
- Abstract
Background: The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib, a second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed Ph-positive acute lymphoblastic leukaemia. Methods: CA180-372/COG AALL1122 was a joint Children's Oncology Group (COG) and European intergroup study of post-induction treatment of Ph-positive acute lymphoblastic leukaemia (EsPhALL) open-label, single-arm, phase 2 study. Eligible patients (aged >1 year to <18 years) with newly diagnosed Ph-positive acute lymphoblastic leukaemia and performance status of at least 60% received EsPhALL chemotherapy plus dasatinib 60 mg/m2 orally once daily from day 15 of induction. Patients with minimal residual disease of at least 0·05% after induction 1B or who were positive for minimal residual disease after the three consolidation blocks were classified as high risk and allocated to receive haematopoietic stem-cell transplantation (HSCT) in first complete remission. The remaining patients were considered standard risk and received chemotherapy plus dasatinib for 2 years. The primary endpoint was the 3-year event-free survival of dasatinib plus chemotherapy compared with external historical controls. The trial was considered positive if one of the following conditions was met: superiority over chemotherapy alone in the AIEOP-BFM 2000 high-risk group; or non-inferiority (with a margin of –5%) or superiority to imatinib plus chemotherapy in the EsPhALL 2010 cohort. All participants who received at least one dose of dasatinib were included in the safety and efficacy analyses. This trial was registered with ClinicalTrials.gov, NCT01460160, and recruitment is closed. Findings: Between March 13, 2012, and May 27, 2014, 109 patients were enrolled at 69 sites (including 51 COG sites in t
- Published
- 2023
6. Pusa HQPM-7 Improved
- Author
-
Hossain, F., Muthusamy, V., Gupta, H. S., Zunjare, R. U., Bhat, J. S., Nepolean, T., Mallikarjuna, M. G., Mukri, G., Kaul, J., Gadag, R. N., Saha, S., Jha, S. K., Manjaiah, K. M., Basu, S., Gogoi, R., Pooniya, V., Parihar, C. M., Kapasia, M., Kumar, R., Pal, D., Bhavi, B. G., Devidas, M., Dass, S., Pal, D., Mahla, J.C., Dhanju, K. S., Singh, D.P., Pal, Rishi, and Kamboj, M.C.
- Published
- 2022
7. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials
- Author
-
Raetz, E, Rebora, P, Conter, V, Schrappe, M, Devidas, M, Escherich, G, Imai, C, De Moerloose, B, Schmiegelow, K, Burns, M, Elitzur, S, Pieters, R, Attarbaschi, A, Yeoh, A, Pui, C, Stary, J, Cario, G, Bodmer, N, Moorman, A, Buldini, B, Vora, A, Valsecchi, M, Raetz, Elizabeth A, Rebora, Paola, Conter, Valentino, Schrappe, Martin, Devidas, Meenakshi, Escherich, Gabriele, Imai, Chihaya, De Moerloose, Barbara, Schmiegelow, Kjeld, Burns, Melissa A, Elitzur, Sarah, Pieters, Rob, Attarbaschi, Andishe, Yeoh, Allen, Pui, Ching-Hon, Stary, Jan, Cario, Gunnar, Bodmer, Nicole, Moorman, Anthony V, Buldini, Barbara, Vora, Ajay, Valsecchi, Maria Grazia, Raetz, E, Rebora, P, Conter, V, Schrappe, M, Devidas, M, Escherich, G, Imai, C, De Moerloose, B, Schmiegelow, K, Burns, M, Elitzur, S, Pieters, R, Attarbaschi, A, Yeoh, A, Pui, C, Stary, J, Cario, G, Bodmer, N, Moorman, A, Buldini, B, Vora, A, Valsecchi, M, Raetz, Elizabeth A, Rebora, Paola, Conter, Valentino, Schrappe, Martin, Devidas, Meenakshi, Escherich, Gabriele, Imai, Chihaya, De Moerloose, Barbara, Schmiegelow, Kjeld, Burns, Melissa A, Elitzur, Sarah, Pieters, Rob, Attarbaschi, Andishe, Yeoh, Allen, Pui, Ching-Hon, Stary, Jan, Cario, Gunnar, Bodmer, Nicole, Moorman, Anthony V, Buldini, Barbara, Vora, Ajay, and Valsecchi, Maria Grazia
- Abstract
PURPOSE Historically, patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission at the end of induction (EOI) have had poor long-term survival. The goal of this study was to examine the efficacy of contemporary therapy, including allogeneic hematopoietic stem cell transplantation (HSCT) in first remission (CR1).METHODSInduction failure (IF) was defined as the persistence of at least 5% bone marrow (BM) lymphoblasts and/or extramedullary disease after 4-6 weeks of induction chemotherapy. Disease features and clinical outcomes were reported in 325 of 6,167 (5%) patients age 21 years and younger treated in 14 cooperative study groups between 2000 and 2018.RESULTSWith a median follow-up period of 6.4 years (range, 0.3-17.9 years), the 10-year overall survival (OS) was 54.7% (SE = 2.9), which is significantly higher than the 27.6% (SE = 2.9) observed in the historical cohort from 1985 to 2000. There was no significant impact of sex, age, white blood cell count, central nervous system disease status, T-cell maturity, or BM disease burden at EOI on OS. Postinduction complete remission (CR) was achieved in 93% of patients with 10-year OS of 59.6% (SE = 3.1%) and disease-free survival (DFS) of 56.3% (SE = 3.1%). Among the patients who achieved CR, 72% underwent HSCT and their 10-year DFS (with a 190-day landmark) was significantly better than nontransplanted patients (63.8% [SE = 3.6] v 45.5% [SE = 7.1]; P =.005), with OS of 66.2% (SE = 3.6) versus 50.8% (SE = 6.8); P =.10, respectively.CONCLUSIONOutcomes for patients age 21 years and younger with T-ALL and IF have improved in the contemporary treatment era with a DFS benefit among those undergoing HSCT in CR1. However, outcomes still lag considerably behind those who achieve remission at EOI, warranting investigation of new treatment approaches.
- Published
- 2023
8. Kerala in Microcosm
- Author
-
Devidas M
- Published
- 2016
9. PP100 [Global health » Resource limited settings]: PEDIATRIC EARLY WARNING SYSTEMS (PEWS) REDUCE CLINICAL DETERIORATION EVENT MORTALITY FOR CHILDREN WITH CANCER IN RESOURCE-LIMITED HOSPITALS: A MULTICENTER STUDY IN LATIN AMERICA
- Author
-
Agulnik, A., primary, Carrillo, A. K., additional, Muniz Talavera, H., additional, Wang, H., additional, Gonzalez Ruiz, A., additional, Cárdenas, A., additional, Garza, M., additional, Conde, T., additional, Soberanis, D., additional, Méndez, A., additional, Diaz, R., additional, Martinez Soria, R., additional, Miralda, S., additional, Mora Robles, L., additional, Pineda, E., additional, Rivera, J., additional, Villanueva Hoyos, E., additional, Devidas, M., additional, Rodriguez Galindo, C., additional, and Evat Study Group, T., additional
- Published
- 2022
- Full Text
- View/download PDF
10. A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY
- Author
-
Meyer, L., primary, Roy, Ritu P., additional, Huang, B., additional, Kimura, S., additional, Polonen, Petri, additional, Delgado-Martin, C., additional, Vincent, T., additional, Ryan, T., additional, Wood, B., additional, Liu, Y., additional, Zhang, J., additional, Mullighan, C., additional, Horton, T., additional, Loh, M., additional, Devidas, M., additional, Raetz, E., additional, Hayashi, R., additional, Winter, S., additional, Dunsmore, K., additional, Hunger, S., additional, Teachey, D., additional, Hermiston, M., additional, and Olshen, Adam B., additional
- Published
- 2022
- Full Text
- View/download PDF
11. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
- Author
-
Mukkada, S, Bhakta, N, Chantada, G, Chen, Y, Vedaraju, Y, Faughnan, L, Homsi, M, Muniz-Talavera, H, Ranadive, R, Metzger, M, Friedrich, P, Agulnik, A, Jeha, S, Lam, C, Dalvi, R, Hessissen, L, Moreira, D, Santana, V, Sullivan, M, Bouffet, E, Caniza, M, Devidas, M, Pritchard-Jones, K, Rodriguez-Galindo, C, Ribelles, A, Balduzzi, A, Elhaddad, A, Casanovas, A, Garcia Velazquez, A, Laptsevich, A, Chang, A, F. Sampaio A., L, Gonzalez Prieto, A, Lassaletta, A, Suarez M, A, Alcasabas, A, Colita, A, Morales La Madrid, A, Samudio, A, Tondo, A, Colombini, A, Kattamis, A, Lopez Facundo, N, Bhattacharyya, A, Alimi, A, Phulpin, A, Vakrmanova, B, Aksoy, B, Brethon, B, Kobuin, J, Nolasco Monteiro, C, Paillard, C, Vezina, C, Ceyhun, B, Hentea, C, Meazza, C, Ortiz-Morales, D, Solorzano, R, Arce Cabrera, D, Zama, D, Ghosh, D, Ramirez-Rivera, D, Calle Jara, D, Janic, D, Rey Helo, E, Gouache, E, Guerrero Quiroz, E, Lopez, E, Thebault, E, Maradiegue, E, de Berranger, E, Ebeid, F, Galaverna, F, Antillon-Klussmann, F, Espinoza Chacur, F, Negro, F, Carraro, F, Compagno, F, Barriga, F, Tamayo Pedraza, G, Sanchez Fernandez, G, Naidu, G, Tokuc, G, Alias, H, B Segocio, H, Boudiaf, H, Asetre Luna, I, Maia, I, Astigarraga, I, Maza, I, Montoya Vasquez, J, Jazbec, J, Lazic, J, Beck Dean, J, Rouger-Gaudichon, J, Contreras Gonzalez, J, Huerta Aragones, J, Fuster, J, Quintana, J, Palma, J, Svojgr, K, Quintero, K, Malic Tudor, K, Georgantzi, K, P Schultz, K, Urena Horno, L, Fraquelli, L, Meneghello, L, Shalaby, L, Macias Mora, L, A Renner, L, Nunes Silva, L, Sisinni, L, Hammad, M, Fernandez Sanmartin, M, Zubieta A, C, Drozdowski, M, Kourti, M, Palladino, M, Miranda Madrazo, M, Poiree, M, Popova, M, Melgar, M, Baragano, M, Aviles-Robles, M, Provenzi, M, Mendes Lins, M, Fatih Orhan, M, Villarroel, M, Jeronimo, M, Varas Palma, M, Rafie Raza, M, M Justin, M, Shaheen, N, Dominguez-Pinilla, N, Whipple, N, Andre, N, Hrusak, O, Velasco Puyo, P, Zacasa Vargas, P, Olate Mellado, P, Yola Gassant, P, Diaz Romero, P, De Santis, R, Kebudi, R, Boranbayeva, R, Vasquez, R, Segura, R, Rosado, R, Gomez, S, Raimbault, S, Gunasekera, S, Makkeyah, S, Buyukkapu Bay, S, M Gomez, S, Bouttefroy, S, Islam, S, Abouelnaga, S, Torres, S, Cesaro, S, Nunes, S, Rouxinol, S, Bhaumik, S, Saliyeva, S, Inostroza, T, Velasquez, T, Hnin, T, Noren-Nystrom, U, Baretta, V, Jimenez-Antolinez, Y, Perez Alonso, V, Ayer Miller, V, Gandemer, V, Lotero, V, Mishkova, V, Gomez-Garcia, W, Margaryan, Y, Syed, Y, Mukkada S., Bhakta N., Chantada G. L., Chen Y., Vedaraju Y., Faughnan L., Homsi M. R., Muniz-Talavera H., Ranadive R., Metzger M., Friedrich P., Agulnik A., Jeha S., Lam C., Dalvi R., Hessissen L., Moreira D. C., Santana V. M., Sullivan M., Bouffet E., Caniza M. A., Devidas M., Pritchard-Jones K., Rodriguez-Galindo C., Ribelles A. J., Balduzzi A., Elhaddad A., Casanovas A., Garcia Velazquez A., Laptsevich A., Chang A., F. Sampaio A. L., Gonzalez Prieto A., Lassaletta A., Suarez M A., Alcasabas A. P., Colita A., Morales La Madrid A., Samudio A., Tondo A., Colombini A., Kattamis A., Lopez Facundo N. A., Bhattacharyya A., Alimi A., Phulpin A., Vakrmanova B., Aksoy B. A., Brethon B., Kobuin J. B., Nolasco Monteiro C., Paillard C., Vezina C., Ceyhun B., Hentea C., Meazza C., Ortiz-Morales D., Solorzano R. D., Arce Cabrera D., Zama D., Ghosh D., Ramirez-Rivera D., Calle Jara D. A., Janic D., Rey Helo E., Gouache E., Guerrero Quiroz E., Lopez E., Thebault E., Maradiegue E., de Berranger E., Ebeid F. S. E., Galaverna F., Antillon-Klussmann F., Espinoza Chacur F., Negro F. D., Carraro F., Compagno F., Barriga F., Tamayo Pedraza G., Sanchez Fernandez G., Naidu G., Tokuc G., Alias H., B Segocio H. G., Boudiaf H., Asetre Luna I., Maia I., Astigarraga I., Maza I., Montoya Vasquez J. E., Jazbec J., Lazic J., Beck Dean J., Rouger-Gaudichon J., Contreras Gonzalez J. C., Huerta Aragones J., Fuster J. L., Quintana J., Palma J., Svojgr K., Quintero K., Malic Tudor K., Georgantzi K., P Schultz K. A., Urena Horno L., Fraquelli L., Meneghello L., Shalaby L., Macias Mora L. L., A Renner L., Nunes Silva L., Sisinni L., Hammad M., Fernandez Sanmartin M., Zubieta A C. M., Drozdowski M. C., Kourti M., Palladino M. M., Miranda Madrazo M. R., Poiree M., Popova M., Melgar M., Baragano M., Aviles-Robles M. J., Provenzi M., Mendes Lins M., Fatih Orhan M., Villarroel M., Jeronimo M., Varas Palma M., Rafie Raza M., M Justin M., Shaheen N., Dominguez-Pinilla N., Whipple N. S., Andre N., Hrusak O., Velasco Puyo P., Zacasa Vargas P., Olate Mellado P., Yola Gassant P., Diaz Romero P., De Santis R., Kebudi R., Boranbayeva R., Vasquez R., Segura R. A., Rosado R. E., Gomez S., Raimbault S., Gunasekera S., Makkeyah S. M., Buyukkapu Bay S., M Gomez S., Bouttefroy S., Islam S., Abouelnaga S., Torres S. F., Cesaro S., Nunes S., Rouxinol S., Bhaumik S., Saliyeva S., Inostroza T., Velasquez T., Hnin T. M., Noren-Nystrom U., Baretta V., Jimenez-Antolinez Y. V., Perez Alonso V., Ayer Miller V., Gandemer V., Lotero V., Mishkova V., Gomez-Garcia W., Margaryan Y., Syed Y., Mukkada, S, Bhakta, N, Chantada, G, Chen, Y, Vedaraju, Y, Faughnan, L, Homsi, M, Muniz-Talavera, H, Ranadive, R, Metzger, M, Friedrich, P, Agulnik, A, Jeha, S, Lam, C, Dalvi, R, Hessissen, L, Moreira, D, Santana, V, Sullivan, M, Bouffet, E, Caniza, M, Devidas, M, Pritchard-Jones, K, Rodriguez-Galindo, C, Ribelles, A, Balduzzi, A, Elhaddad, A, Casanovas, A, Garcia Velazquez, A, Laptsevich, A, Chang, A, F. Sampaio A., L, Gonzalez Prieto, A, Lassaletta, A, Suarez M, A, Alcasabas, A, Colita, A, Morales La Madrid, A, Samudio, A, Tondo, A, Colombini, A, Kattamis, A, Lopez Facundo, N, Bhattacharyya, A, Alimi, A, Phulpin, A, Vakrmanova, B, Aksoy, B, Brethon, B, Kobuin, J, Nolasco Monteiro, C, Paillard, C, Vezina, C, Ceyhun, B, Hentea, C, Meazza, C, Ortiz-Morales, D, Solorzano, R, Arce Cabrera, D, Zama, D, Ghosh, D, Ramirez-Rivera, D, Calle Jara, D, Janic, D, Rey Helo, E, Gouache, E, Guerrero Quiroz, E, Lopez, E, Thebault, E, Maradiegue, E, de Berranger, E, Ebeid, F, Galaverna, F, Antillon-Klussmann, F, Espinoza Chacur, F, Negro, F, Carraro, F, Compagno, F, Barriga, F, Tamayo Pedraza, G, Sanchez Fernandez, G, Naidu, G, Tokuc, G, Alias, H, B Segocio, H, Boudiaf, H, Asetre Luna, I, Maia, I, Astigarraga, I, Maza, I, Montoya Vasquez, J, Jazbec, J, Lazic, J, Beck Dean, J, Rouger-Gaudichon, J, Contreras Gonzalez, J, Huerta Aragones, J, Fuster, J, Quintana, J, Palma, J, Svojgr, K, Quintero, K, Malic Tudor, K, Georgantzi, K, P Schultz, K, Urena Horno, L, Fraquelli, L, Meneghello, L, Shalaby, L, Macias Mora, L, A Renner, L, Nunes Silva, L, Sisinni, L, Hammad, M, Fernandez Sanmartin, M, Zubieta A, C, Drozdowski, M, Kourti, M, Palladino, M, Miranda Madrazo, M, Poiree, M, Popova, M, Melgar, M, Baragano, M, Aviles-Robles, M, Provenzi, M, Mendes Lins, M, Fatih Orhan, M, Villarroel, M, Jeronimo, M, Varas Palma, M, Rafie Raza, M, M Justin, M, Shaheen, N, Dominguez-Pinilla, N, Whipple, N, Andre, N, Hrusak, O, Velasco Puyo, P, Zacasa Vargas, P, Olate Mellado, P, Yola Gassant, P, Diaz Romero, P, De Santis, R, Kebudi, R, Boranbayeva, R, Vasquez, R, Segura, R, Rosado, R, Gomez, S, Raimbault, S, Gunasekera, S, Makkeyah, S, Buyukkapu Bay, S, M Gomez, S, Bouttefroy, S, Islam, S, Abouelnaga, S, Torres, S, Cesaro, S, Nunes, S, Rouxinol, S, Bhaumik, S, Saliyeva, S, Inostroza, T, Velasquez, T, Hnin, T, Noren-Nystrom, U, Baretta, V, Jimenez-Antolinez, Y, Perez Alonso, V, Ayer Miller, V, Gandemer, V, Lotero, V, Mishkova, V, Gomez-Garcia, W, Margaryan, Y, Syed, Y, Mukkada S., Bhakta N., Chantada G. L., Chen Y., Vedaraju Y., Faughnan L., Homsi M. R., Muniz-Talavera H., Ranadive R., Metzger M., Friedrich P., Agulnik A., Jeha S., Lam C., Dalvi R., Hessissen L., Moreira D. C., Santana V. M., Sullivan M., Bouffet E., Caniza M. A., Devidas M., Pritchard-Jones K., Rodriguez-Galindo C., Ribelles A. J., Balduzzi A., Elhaddad A., Casanovas A., Garcia Velazquez A., Laptsevich A., Chang A., F. Sampaio A. L., Gonzalez Prieto A., Lassaletta A., Suarez M A., Alcasabas A. P., Colita A., Morales La Madrid A., Samudio A., Tondo A., Colombini A., Kattamis A., Lopez Facundo N. A., Bhattacharyya A., Alimi A., Phulpin A., Vakrmanova B., Aksoy B. A., Brethon B., Kobuin J. B., Nolasco Monteiro C., Paillard C., Vezina C., Ceyhun B., Hentea C., Meazza C., Ortiz-Morales D., Solorzano R. D., Arce Cabrera D., Zama D., Ghosh D., Ramirez-Rivera D., Calle Jara D. A., Janic D., Rey Helo E., Gouache E., Guerrero Quiroz E., Lopez E., Thebault E., Maradiegue E., de Berranger E., Ebeid F. S. E., Galaverna F., Antillon-Klussmann F., Espinoza Chacur F., Negro F. D., Carraro F., Compagno F., Barriga F., Tamayo Pedraza G., Sanchez Fernandez G., Naidu G., Tokuc G., Alias H., B Segocio H. G., Boudiaf H., Asetre Luna I., Maia I., Astigarraga I., Maza I., Montoya Vasquez J. E., Jazbec J., Lazic J., Beck Dean J., Rouger-Gaudichon J., Contreras Gonzalez J. C., Huerta Aragones J., Fuster J. L., Quintana J., Palma J., Svojgr K., Quintero K., Malic Tudor K., Georgantzi K., P Schultz K. A., Urena Horno L., Fraquelli L., Meneghello L., Shalaby L., Macias Mora L. L., A Renner L., Nunes Silva L., Sisinni L., Hammad M., Fernandez Sanmartin M., Zubieta A C. M., Drozdowski M. C., Kourti M., Palladino M. M., Miranda Madrazo M. R., Poiree M., Popova M., Melgar M., Baragano M., Aviles-Robles M. J., Provenzi M., Mendes Lins M., Fatih Orhan M., Villarroel M., Jeronimo M., Varas Palma M., Rafie Raza M., M Justin M., Shaheen N., Dominguez-Pinilla N., Whipple N. S., Andre N., Hrusak O., Velasco Puyo P., Zacasa Vargas P., Olate Mellado P., Yola Gassant P., Diaz Romero P., De Santis R., Kebudi R., Boranbayeva R., Vasquez R., Segura R. A., Rosado R. E., Gomez S., Raimbault S., Gunasekera S., Makkeyah S. M., Buyukkapu Bay S., M Gomez S., Bouttefroy S., Islam S., Abouelnaga S., Torres S. F., Cesaro S., Nunes S., Rouxinol S., Bhaumik S., Saliyeva S., Inostroza T., Velasquez T., Hnin T. M., Noren-Nystrom U., Baretta V., Jimenez-Antolinez Y. V., Perez Alonso V., Ayer Miller V., Gandemer V., Lotero V., Mishkova V., Gomez-Garcia W., Margaryan Y., and Syed Y.
- Abstract
Background: Previous studies have shown that children and adolescents with COVID-19 generally have mild disease. Children and adolescents with cancer, however, can have severe disease when infected with respiratory viruses. In this study, we aimed to understand the clinical course and outcomes of SARS-CoV-2 infection in children and adolescents with cancer. Methods: We did a cohort study with data from 131 institutions in 45 countries. We created the Global Registry of COVID-19 in Childhood Cancer to capture de-identified data pertaining to laboratory-confirmed SARS-CoV-2 infections in children and adolescents (<19 years) with cancer or having received a haematopoietic stem-cell transplantation. There were no centre-specific exclusion criteria. The registry was disseminated through professional networks through email and conferences and health-care providers were invited to submit all qualifying cases. Data for demographics, oncological diagnosis, clinical course, and cancer therapy details were collected. Primary outcomes were disease severity and modification to cancer-directed therapy. The registry remains open to data collection. Findings: Of 1520 submitted episodes, 1500 patients were included in the study between April 15, 2020, and Feb 1, 2021. 1319 patients had complete 30-day follow-up. 259 (19·9%) of 1301 patients had a severe or critical infection, and 50 (3·8%) of 1319 died with the cause attributed to COVID-19 infection. Modifications to cancer-directed therapy occurred in 609 (55·8%) of 1092 patients receiving active oncological treatment. Multivariable analysis revealed several factors associated with severe or critical illness, including World Bank low-income or lower-middle-income (odds ratio [OR] 5·8 [95% CI 3·8–8·8]; p<0·0001) and upper-middle-income (1·6 [1·2–2·2]; p=0·0024) country status; age 15–18 years (1·6 [1·1–2·2]; p=0·013); absolute lymphocyte count of 300 or less cells per mm3 (2·5 [1·8–3·4]; p<0·0001), absolute neutrophil count
- Published
- 2021
12. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children’s Oncology Group Study
- Author
-
Matlawska-Wasowska, K, Kang, H, Devidas, M, Wen, J, Harvey, R C, Nickl, C K, Ness, S A, Rusch, M, Li, Y, Onozawa, M, Martinez, C, Wood, B L, Asselin, B L, Chen, I-M, Roberts, K G, Baruchel, A, Soulier, J, Dombret, H, Zhang, J, Larson, R S, Raetz, E A, Carroll, W L, Winick, N J, Aplan, P D, Loh, M L, Mullighan, C G, Hunger, S P, Heerema, N A, Carroll, A J, Dunsmore, K P, and Winter, S S
- Published
- 2016
- Full Text
- View/download PDF
13. Analysis of Load Dynamics in Induction Melting Furnace and Improved Power Quality With Phase Shift Modulated LLC Resonant IGBT Inverter
- Author
-
Choudhary, Devidas M. and Kotwal, Chetan D
- Abstract
A dynamic load profile is experienced by the power topology to which the induction melting furnace (IMF) is coupled when an iron scrap is being melted in the furnace. This load profile necessitates continuous correction in silicon-controlled rectifier (SCR)-based front-end converter as well as adjustment in the switching frequency of an inverter in a conventional 12-pulse SCR current source inverter (CSI-SCR) design. This correction on both sides of the converter results in harmonics and interharmonics, which gets injected into the supply line current, degrading the distribution grid’s power quality. The line current total harmonic distortion (THD) is observed to be around 16%–19.5% which is beyond the permissible limit (< 12%) as per IEEE 519–2014 standard. This article investigates the dynamic load profile of the IMF system based on simulation and extensive practical field data from existing running IMF. In this article, LLC resonant insulated gate bipolar transistor (IGBT) inverter is proposed for an iron scrap melting application. In the proposed topology, in which the practical load profile of the furnace is taken into account, the front-end converter is an uncontrolled diode rectifier, and the power to the furnace load is controlled by a combination of phase shift modulation (PSM) and frequency control of the IGBT inverter. A prototype model of 100 kW is designed, fabricated, and tested in the field to validate the concept. The proposed topology reduced the line current THD from 19.5% to 11.6%, meeting the required standard. In addition, the system efficiency has improved by 2.05%.
- Published
- 2023
- Full Text
- View/download PDF
14. EE166 Cost-Effectiveness of Treatment Strategies for Severe Hemophilia a Patients in the United States
- Author
-
Bolous, N, primary, Chen, Y, additional, Wang, H, additional, Devidas, M, additional, Bhakta, N, additional, and Reiss, U, additional
- Published
- 2022
- Full Text
- View/download PDF
15. S102: COMPREHENSIVE GENOME CHARACTERIZATION REVEALS NEW SUBTYPES AND MECHANISMS OF ONCOGENE DEREGULATION IN CHILDHOOD T-ALL
- Author
-
Pölönen, P., primary, Elsayed, A., additional, Montefiori, L., additional, Kimura, S., additional, Myers, J., additional, Hedges, D., additional, Xu, J., additional, Hui, Y., additional, Cheng, Z., additional, Fan, Y., additional, Chang, Y., additional, Shraim, R., additional, Devidas, M., additional, Winter, S., additional, Dunsmore, K., additional, Yang, J. J., additional, Vincent, T. L., additional, Tan, K., additional, Chen, C., additional, Newman, H., additional, Loh, M., additional, Raetz, E., additional, Hunger, S. P., additional, Rampersaud, E., additional, Chang, T.-C., additional, Wu, G., additional, Pounds, S., additional, Mullighan, C. G., additional, and Teachey, D. T., additional
- Published
- 2022
- Full Text
- View/download PDF
16. Mobile Apps for the Personal Safety of At-Risk Children and Youth: Scoping Review
- Author
-
Camille Bowen-Forbes, Tilovatul Khondaker, Tania Stafinski, Maliheh Hadizadeh, and Devidas Menon
- Subjects
Information technology ,T58.5-58.64 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundPersonal safety is a widespread public health issue that affects people of all demographics. There is a growing interest in the use of mobile apps for enhancing personal safety, particularly for children and youth at risk, who are among the most vulnerable groups in society. ObjectiveThis study aims to explore what is known about the use of mobile apps for personal safety among children and youth identified to be “at risk.” MethodsA scoping review following published methodological guidelines was conducted. In total, 5 databases (Scopus, SocINDEX, PsycINFO, Compendex, and Inspec Archive) were searched for relevant scholarly articles published between January 2005 and October 2023. The gray literature was searched using Google and Google Scholar search engines. The results were reported using the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. For summarizing the features and users’ experiences of the apps, a published framework for evaluating the quality of mobile health apps for youth was used. ResultsA total of 1986 articles were identified, and 41 (2.1%) were included in the review. Nine personal safety apps were captured and categorized into 4 groups based on the goals of the apps, as follows: dating and sexual violence prevention (n=4, 44% of apps), bullying and school violence prevention (n=2, 22% of apps), self-harm and suicide prevention (n=2, 22% of apps), and homeless youth support (n=1, 11% of apps). Of the 41 articles, 25 (61%) provided data solely on app descriptions and features, while the remaining 16 (39%) articles provided data on app evaluations and descriptions. Outcomes focused on app engagement, users’ experiences, and effectiveness. Four articles reported on app use, 3 (75%) of which reported relatively high app use. Data on users’ experience were obtained from 13 studies. In general, participants found the app features to be easy to use and useful as educational resources and personal safety tools. Most of the views were positive. Negative perceptions included redundancy of app features and a lack of usefulness. Five apps were evaluated for effectiveness (n=2, 40% dating and sexual violence prevention; n=2, 40% self-harm and suicide prevention; and n=1, 20% bullying and school violence prevention) and were all associated with a statistically significant reduction (P=.001 to .048) in harm or risk to participants at the 95% CI. ConclusionsAlthough many personal safety apps are available, few studies have specifically evaluated those designed for youth. However, the evidence suggests that mobile safety apps generally appear to be beneficial for reducing harm to at-risk children and youth without any associated adverse events. Recommendations for future research have been made to strengthen the evidence and increase the availability of effective personal safety apps for children and youth.
- Published
- 2024
- Full Text
- View/download PDF
17. Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study
- Author
-
Sniderman ER, Graetz DE, Agulnik A, Ranadive R, Vedaraju Y, Chen Y, Devidas M, Chantada G, Hessissen L, Dalvi R, Pritchard-Jones K, Rodriguez-Galindo C, and Moreira DC
- Subjects
workforce ,global ,health care personnel ,pediatric oncology ,delivery of health care ,coronavirus disease 2019 (COVID-19) - Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) disrupted pediatric oncology care globally, increasing demands on health care providers (HCPs) who adapted to continue care. This study sought to characterize the pandemic's impact on pediatric oncology HCPs worldwide. METHODS: A 60-item survey focused on changes to clinical care, resources, and effects on clinicians. A diverse subgroup of institutions was purposefully selected for focus groups that explored teamwork, communication, and changes to care delivery. RESULTS: The survey included 311 responses from 213 institutions representing 79 countries. Sixteen institutions participated in 19 multidisciplinary focus groups in 8 languages. Decreased clinical staff availability was cited by 51% of institutions as a major impact. Staffing modifications included decreased provider availability (66% of institutions), roles or responsibility changes, and transfer outside the specialty. Physical effects included frequent COVID-19 illness; 8% of respondents reported HCP deaths. Fifty percent of providers did not have the necessary personal protective equipment. HCPs also experienced psychological distress and financial concerns. Findings indicated more frequent impact on nurses than other providers. Impacts were described across all hospital resource levels, with staffing modifications more frequent in countries with higher COVID-19 incidence (P < .001) and mortality rate (P = .004). Focus groups revealed negative impacts were stabilized by increased teamwork, communication, contributions outside usual roles, policies aimed at optimizing safety, and feeling that they were contributing. CONCLUSIONS: COVID-19 had a profound impact on the pediatric oncology workforce, creating challenging modifications to staffing and resulting in physical, psychological, and financial distress. Despite these challenges, HCPs caring for children with cancer came together to continue to provide high-quality care.
- Published
- 2022
18. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031
- Author
-
Schultz, K R, Carroll, A, Heerema, N A, Bowman, W P, Aledo, A, Slayton, W B, Sather, H, Devidas, M, Zheng, H W, Davies, S M, Gaynon, P S, Trigg, M, Rutledge, R, Jorstad, D, Winick, N, Borowitz, M J, Hunger, S P, Carroll, W L, and Camitta, B
- Published
- 2014
- Full Text
- View/download PDF
19. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome
- Author
-
Harrison, C J, Moorman, A V, Schwab, C, Carroll, A J, Raetz, E A, Devidas, M, Strehl, S, Nebral, K, Harbott, J, Teigler-Schlegel, A, Zimmerman, M, Dastuge, N, Baruchel, A, Soulier, J, Auclerc, M-F, Attarbaschi, A, Mann, G, Stark, B, Cazzaniga, G, Chilton, L, Vandenberghe, P, Forestier, E, Haltrich, I, Raimondi, S C, Parihar, M, Bourquin, J-P, Tchinda, J, Haferlach, C, Vora, A, Hunger, S P, Heerema, N A, and Haas, O A
- Published
- 2014
- Full Text
- View/download PDF
20. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031
- Author
-
Schultz, K R, Devidas, M, Bowman, W P, Aledo, A, Slayton, W B, Sather, H, Zheng, H W, Davies, S M, Gaynon, P S, Trigg, M, Rutledge, R, Jorstad, D, Carroll, A J, Heerema, N, Winick, N, Borowitz, M J, Hunger, S P, Carroll, W L, and Camitta, B
- Published
- 2014
- Full Text
- View/download PDF
21. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
- Author
-
Mukkada S, Bhakta N, Chantada G, Chen Y, Vedaraju Y, Faughnan L, Homsi MR, Muniz-Talavera H, Ranadive R, Metzger M, Friedrich P, Agulnik A, Jeha S, Lam C, Dalvi R, Hessissen L, Moreira DC, Santana VM, Sullivan M, Bouffet E, Caniza MA, Devidas M, Pritchard-Jones K, Rodriguez-Galindo C, and Global Registry of COVID-19 in Childhood Cancer
- Abstract
BACKGROUND: Previous studies have shown that children and adolescents with COVID-19 generally have mild disease. Children and adolescents with cancer, however, can have severe disease when infected with respiratory viruses. In this study, we aimed to understand the clinical course and outcomes of SARS-CoV-2 infection in children and adolescents with cancer. METHODS: We did a cohort study with data from 131 institutions in 45 countries. We created the Global Registry of COVID-19 in Childhood Cancer to capture de-identified data pertaining to laboratory-confirmed SARS-CoV-2 infections in children and adolescents (
- Published
- 2021
22. Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study
- Author
-
Graetz D, Agulnik A, Ranadive R, Vedaraju Y, Chen Y, Chantada G, Metzger ML, Mukkada S, Force LM, Friedrich P, Lam C, Sniderman E, Bhakta N, Hessissen L, Dalvi R, Devidas M, Pritchard-Jones K, Rodriguez-Galindo C, and Moreira DC
- Abstract
BACKGROUND: Although mortality due to COVID-19 has been reportedly low among children with cancer, changes in health-care services due to the pandemic have affected cancer care delivery. This study aimed to assess the effect of the COVID-19 pandemic on childhood cancer care worldwide. METHODS: A cross-sectional survey was distributed to paediatric oncology providers worldwide from June 22 to Aug 21, 2020, through the St Jude Global Alliance and International Society for Paediatric Oncology listservs and regional networks. The survey included 60 questions to assess institution characteristics, the number of patients diagnosed with COVID-19, disruptions to cancer care (eg, service closures and treatment abandonment), adaptations to care, and resources (including availability of clinical staff and personal protective equipment). Surveys were included for analysis if respondents answered at least two thirds of the items, and the responses were analysed at the institutional level. FINDINGS: Responses from 311 health-care professionals at 213 institutions in 79 countries from all WHO regions were included in the analysis. 187 (88%) of 213 centres had the capacity to test for SARS-CoV-2 and a median of two (range 0-350) infections per institutution were reported in children with cancer. 15 (7%) centres reported complete closure of paediatric haematology-oncology services (median 10 days, range 1-75 days). Overall, 2% (5 of 213) of centres were no longer evaluating new cases of suspected cancer, while 43% (90 of 208) of the remaining centers described a decrease in newly diagnosed paediatric cancer cases. 73 (34%) centres reported increased treatment abandonment (ie, failure to initiate cancer therapy or a delay in care of 4 weeks or longer). Changes to cancer care delivery included: reduced surgical care (153 [72%]), blood product shortages (127 [60%]), chemotherapy modifications (121 [57%]), and interruptions to radiotherapy (43 [28%] of 155 institutions that provided radiotherapy before the pandemic). The decreased number of new cancer diagnoses did not vary based on country income status (p=0·14). However, unavailability of chemotherapy agents (p=0·022), treatment abandonment (p
- Published
- 2021
23. The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global
- Author
-
Moreira, DC, Sniderman, E, Mukkada, S, Chantada, G, Bhakta, N, Foster, W, Avula, M, Homsi, MR, Faughan, L, Happ, B, Andujar, A, Sonnenfelt, J, Dalvi, R, Frazier, AL, Hessissen, L, Kearns, PR, Luna-Fineman, S, Moreno, A, Saghir Khan, M, Sullivan, M, Devidas, M, Santana, V, Caniza, M, Pritchard-Jones, K, Rodriguez-Galindo, C, Moreira, DC, Sniderman, E, Mukkada, S, Chantada, G, Bhakta, N, Foster, W, Avula, M, Homsi, MR, Faughan, L, Happ, B, Andujar, A, Sonnenfelt, J, Dalvi, R, Frazier, AL, Hessissen, L, Kearns, PR, Luna-Fineman, S, Moreno, A, Saghir Khan, M, Sullivan, M, Devidas, M, Santana, V, Caniza, M, Pritchard-Jones, K, and Rodriguez-Galindo, C
- Abstract
The COVID-19 pandemic quickly led to an abundance of publications and recommendations, despite a paucity of information on how COVID-19 affects children with cancer. This created a dire need for a trusted resource with curated information and a space for the pediatric oncology community to share experiences. The Global COVID-19 Observatory and Resource Center for Childhood Cancer was developed, launched, and maintained by the International Society of Pediatric Oncology and St. Jude Children's Research Hospital. The three components (Resource Library, Global Registry, and Collaboration Space) complement each other, establishing a mechanism to generate and transfer knowledge rapidly throughout the community.
- Published
- 2021
24. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements
- Author
-
De Lorenzo, P, Moorman, A V, Pieters, R, Dreyer, Z E, Heerema, N A, Carroll, A J, Hunger, S P, Harvey, R, Willman, C L, Devidas, M, Valsecchi, M-G, and Harrison, C J
- Published
- 2014
- Full Text
- View/download PDF
25. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles
- Author
-
Loudin, M G, Wang, J, Eastwood Leung, H-C, Gurusiddappa, S, Meyer, J, Condos, G, Morrison, D, Tsimelzon, A, Devidas, M, Heerema, N A, Carroll, A J, Plon, S E, Hunger, S P, Basso, G, Pession, A, Bhojwani, D, Carroll, W L, and Rabin, K R
- Published
- 2011
- Full Text
- View/download PDF
26. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia
- Author
-
Blink, M, Buitenkamp, T D, van den Heuvel-Eibrink, M M, Danen-van Oorschot, A A, de Haas, V, Reinhardt, D, Klusmann, J-H, Zimmermann, M, Devidas, M, Carroll, A J, Basso, G, Pession, A, Hasle, H, Pieters, R, Rabin, K R, Izraeli, S, and Zwaan, C M
- Published
- 2011
- Full Text
- View/download PDF
27. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report
- Author
-
Gaynon, P S, Angiolillo, A L, Carroll, W L, Nachman, J B, Trigg, M E, Sather, H N, Hunger, S P, and Devidas, M
- Published
- 2010
- Full Text
- View/download PDF
28. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group
- Author
-
Salzer, W L, Devidas, M, Carroll, W L, Winick, N, Pullen, J, Hunger, S P, and Camitta, B A
- Published
- 2010
- Full Text
- View/download PDF
29. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group
- Author
-
Larson Gedman, A, Chen, Q, Kugel Desmoulin, S, Ge, Y, LaFiura, K, Haska, C L, Cherian, C, Devidas, M, Linda, S B, Taub, J W, and Matherly, L H
- Published
- 2009
- Full Text
- View/download PDF
30. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
- Author
-
Nguyen, K, Devidas, M, Cheng, S-C, La, M, Raetz, E A, Carroll, W L, Winick, N J, Hunger, S P, Gaynon, P S, and Loh, M L
- Published
- 2008
- Full Text
- View/download PDF
31. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research
- Author
-
Eapen, M, Zhang, M-J, Devidas, M, Raetz, E, Barredo, J C, Ritchey, A K, Godder, K, Grupp, S, Lewis, V A, Malloy, K, Carroll, W L, Davies, S M, and Camitta, B M
- Published
- 2008
- Full Text
- View/download PDF
32. EE203 The Impact of Varying the Target Population on the Outcome of a Cost-Effectiveness Analysis: Hemophilia B As an Exemplary Disease
- Author
-
Bolous, N., Chen, Y., Devidas, M., Reiss, U., and Bhakta, N.
- Published
- 2023
- Full Text
- View/download PDF
33. EE89 The Impact of Different Discounting Rates on Cost-Effectiveness Outcomes in Chronic Disease Populations: Hemophilia A As an Exemplary Disease
- Author
-
Bolous, N., Chen, Y., Devidas, M., Reiss, U., and Bhakta, N.
- Published
- 2023
- Full Text
- View/download PDF
34. COVD-04. CHARACTERISTICS OF SARS-COV-2 IN 64 CHILDREN WITH CNS TUMORS: A REPORT FROM THE SIOP/ST. JUDE CHILDREN’S RESEARCH HOSPITAL (SJCRH) GLOBAL COVID-19 CHILDHOOD CANCER REGISTRY
- Author
-
Moreira, D, Bouffet, E, Bhakta, N, Chantada, G, Chen, Y, Faughnan, L, Vedaraju, Y, Avula, M, Homsi, M, Naidu, P, Pappas, A, Ranadive, R, Santana, V, Sullivan, M, Baroni, L, Caniza, M, Devidas, M, Pritchard-Jones, K, Rodriguez-Galindo, C, Mukkada, S, Moreira, D, Bouffet, E, Bhakta, N, Chantada, G, Chen, Y, Faughnan, L, Vedaraju, Y, Avula, M, Homsi, M, Naidu, P, Pappas, A, Ranadive, R, Santana, V, Sullivan, M, Baroni, L, Caniza, M, Devidas, M, Pritchard-Jones, K, Rodriguez-Galindo, C, and Mukkada, S
- Abstract
BACKGROUND The GCCCR is a collaboration between SIOP and SJCRH to describe the natural history of SARS-CoV-2 in children with cancer across the world. METHODS The GCCCR is a deidentified registry of patients <19 years of age with cancer or recipients of a hematopoietic stem cell transplant and laboratory-confirmed SARS-CoV-2 infection. Demographic data, cancer diagnosis, cancer-directed therapy, and clinical characteristics of SARS-CoV-2 infection were collected. Outcomes were collected at 30-days and 60-days post infection. RESULTS As of August 10th 2020, the GCCCR included 730 cases from 35 countries, including 64 children with CNS tumors (8.8%) from 17 countries. The most frequent diagnoses were embryonal tumors (31.2%) and low-grade glioma (17.2%). Thirty-nine (60.9%) children were asymptomatic from infection, while 19 (29.7%) patients required hospital admission and 2 (6.3%) transferred to the intensive care unit. There was a significant association between infection severity and ANC <500 (p=0.04). At the time of infection, 44 (68.8%) patients were undergoing cancer-directed therapy. Thirty-two cases have follow-up data. No modification in cancer-directed therapy occurred in 11 (34.4%) patients, while chemotherapy was modified in 6 (18.8%), radiotherapy delayed in 2 (6.3%), and surgery postponed in 1 (3.1%). No patients died from SARS-CoV-2 infection, although 2 died from non-COVID-19 related causes. CONCLUSION The frequency and severity of COVID infection among children with CNS tumors appears to be proportionally lower compared to other children with cancer. Although this is the largest cohort of patients reported to date, additional insight is needed, including the effects of treatment modifications on outcomes.
- Published
- 2020
35. Exploring the Impact of In Basket Metrics on the Adoption of a New Electronic Health Record System Among Specialists in a Tertiary Hospital in Alberta: Descriptive Study
- Author
-
Melita Avdagovska, Craig Kuziemsky, Helia Koosha, Maliheh Hadizadeh, Robert P Pauly, Timothy Graham, Tania Stafinski, David Bigam, Narmin Kassam, and Devidas Menon
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundHealth care organizations implement electronic health record (EHR) systems with the expectation of improved patient care and enhanced provider performance. However, while these technologies hold the potential to create improved care and system efficiencies, they can also lead to unintended negative consequences, such as patient safety issues, communication problems, and provider burnout. ObjectiveThis study aims to document metrics related to the In Basket communication hub (time in In Basket per day, time in In Basket per appointment, In Basket messages received per day, and turnaround time) of the EHR system implemented by Alberta Health Services, the province-wide health delivery system called Connect Care (Epic Systems). The objective was to identify how a newly implemented EHR system was used, the timing of its use, and the duration of use specifically related to In Basket activities. MethodsA descriptive study was conducted. Due to the diversity of specialties, the providers were grouped into medical and surgical based on previous similar studies. The participants were further subgrouped based on their self-reported clinical full-time equivalent (FTE ) measure. This resulted in 3 subgroups for analysis: medical FTE 0.5, and surgical (all of whom reported FTE >0.5). The analysis was limited to outpatient clinical interactions and explicitly excluded inpatient activities. ResultsA total of 72 participants from 19 different specialties enrolled in this study. The providers had, on average, 8.31 appointments per day during the reporting periods. The providers received, on average, 21.93 messages per day, and they spent 7.61 minutes on average in the time in In Basket per day metric and 1.84 minutes on average in the time in In Basket per appointment metric. The time for the providers to mark messages as done (turnaround time) was on average 11.45 days during the reporting period. Although the surgical group had, on average, approximately twice as many appointments per scheduled day, they spent considerably less connected time (based on almost all time metrics) than the medical group. However, the surgical group took much longer than the medical group to mark messages as done (turnaround time). ConclusionsWe observed a range of patterns with no consistent direction. There does not seem to be evidence of a “learning curve,” which would have shown a consistent reduction in time spent on the system over time due to familiarity and experience. While this study does not show how the included metrics could be used as predictors of providers’ satisfaction or feelings of burnout, the use trends could be used to start discussions about future Canadian studies needed in this area.
- Published
- 2024
- Full Text
- View/download PDF
36. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
- Author
-
Mehta, P A, Davies, S M, Kumar, A, Devidas, M, Lee, S, Zamzow, T, Elliott, J, Villanueva, J, Pullen, J, Zewge, Y, and Filipovich, A
- Published
- 2006
- Full Text
- View/download PDF
37. 049 - A TARGETED GENE EXPRESSION CLASSIFIER IDENTIFIES PEDIATRIC T-ALL PATIENTS AT HIGH RISK FOR END INDUCTION MINIMAL RESIDUAL DISEASE POSITIVITY
- Author
-
Meyer, L., Roy, Ritu P., Huang, B., Kimura, S., Polonen, Petri, Delgado-Martin, C., Vincent, T., Ryan, T., Wood, B., Liu, Y., Zhang, J., Mullighan, C., Horton, T., Loh, M., Devidas, M., Raetz, E., Hayashi, R., Winter, S., Dunsmore, K., Hunger, S., Teachey, D., Hermiston, M., and Olshen, Adam B.
- Published
- 2022
- Full Text
- View/download PDF
38. ANTI-METABOLITE THERAPY FOR LESSER-RISK B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA OF CHILDHOOD: PEDIATRIC ONCOLOGY GROUP (POG) STUDY 9201: O.148
- Author
-
Chauvenet, A., Martin, P. L., Bell, B., Kurtzburg, J., Pullen, J., Shuster, J., Devidas, M., Linda, S., and Camitta, B.
- Published
- 2005
39. Axial transformation of the profunda femoris vein
- Author
-
Raju, Seshadri, Fountain, Todd, Neglén, Peter, and Devidas, M.
- Published
- 1998
40. The genetic basis and cell of origin of mixed phenotype acute leukaemia.
- Author
-
Alexander, TB, Gu, Z, Iacobucci, I, Dickerson, K, Choi, JK, Xu, B, Payne-Turner, D, Yoshihara, H, Loh, ML, Horan, J, Buldini, B, Basso, G, Elitzur, S, de Haas, V, Zwaan, CM, Yeoh, A, Reinhardt, D, Tomizawa, D, Kiyokawa, N, Lammens, T, De Moerloose, B, Catchpoole, D, Hori, H, Moorman, A, Moore, AS, Hrusak, O, Meshinchi, S, Orgel, E, Devidas, M, Borowitz, M, Wood, B, Heerema, NA, Carrol, A, Yang, Y-L, Smith, MA, Davidsen, TM, Hermida, LC, Gesuwan, P, Marra, MA, Ma, Y, Mungall, AJ, Moore, RA, Jones, SJM, Valentine, M, Janke, LJ, Rubnitz, JE, Pui, C-H, Ding, L, Liu, Y, Zhang, J, Nichols, KE, Downing, JR, Cao, X, Shi, L, Pounds, S, Newman, S, Pei, D, Guidry Auvil, JM, Gerhard, DS, Hunger, SP, Inaba, H, Mullighan, CG, Alexander, TB, Gu, Z, Iacobucci, I, Dickerson, K, Choi, JK, Xu, B, Payne-Turner, D, Yoshihara, H, Loh, ML, Horan, J, Buldini, B, Basso, G, Elitzur, S, de Haas, V, Zwaan, CM, Yeoh, A, Reinhardt, D, Tomizawa, D, Kiyokawa, N, Lammens, T, De Moerloose, B, Catchpoole, D, Hori, H, Moorman, A, Moore, AS, Hrusak, O, Meshinchi, S, Orgel, E, Devidas, M, Borowitz, M, Wood, B, Heerema, NA, Carrol, A, Yang, Y-L, Smith, MA, Davidsen, TM, Hermida, LC, Gesuwan, P, Marra, MA, Ma, Y, Mungall, AJ, Moore, RA, Jones, SJM, Valentine, M, Janke, LJ, Rubnitz, JE, Pui, C-H, Ding, L, Liu, Y, Zhang, J, Nichols, KE, Downing, JR, Cao, X, Shi, L, Pounds, S, Newman, S, Pei, D, Guidry Auvil, JM, Gerhard, DS, Hunger, SP, Inaba, H, and Mullighan, CG
- Abstract
Mixed phenotype acute leukaemia (MPAL) is a high-risk subtype of leukaemia with myeloid and lymphoid features, limited genetic characterization, and a lack of consensus regarding appropriate therapy. Here we show that the two principal subtypes of MPAL, T/myeloid (T/M) and B/myeloid (B/M), are genetically distinct. Rearrangement of ZNF384 is common in B/M MPAL, and biallelic WT1 alterations are common in T/M MPAL, which shares genomic features with early T-cell precursor acute lymphoblastic leukaemia. We show that the intratumoral immunophenotypic heterogeneity characteristic of MPAL is independent of somatic genetic variation, that founding lesions arise in primitive haematopoietic progenitors, and that individual phenotypic subpopulations can reconstitute the immunophenotypic diversity in vivo. These findings indicate that the cell of origin and founding lesions, rather than an accumulation of distinct genomic alterations, prime tumour cells for lineage promiscuity. Moreover, these findings position MPAL in the spectrum of immature leukaemias and provide a genetically informed framework for future clinical trials of potential treatments for MPAL.
- Published
- 2018
41. Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
- Author
-
Galimberti, S, Devidas, M, Lucenti, A, Cazzaniga, G, Möricke, A, Bartram, C, Mann, G, Carroll, W, Winick, N, Borowitz, M, Wood, B, Basso, G, Conter, V, Zimmermann, M, Suciu, S, Biondi, A, Schrappe, M, Hunger, S, Valsecchi, M, Galimberti, Stefania, Devidas, Meenakshi, Lucenti, Ausiliatrice, Cazzaniga, Giovanni, Möricke, Anja, Bartram, Claus R, Mann, Georg, Carroll, William, Winick, Naomi, Borowitz, Michael, Wood, Brent, Basso, Giuseppe, Conter, Valentino, Zimmermann, Martin, Suciu, Stefan, Biondi, Andrea, Schrappe, Martin, Hunger, Stephen P, Valsecchi, Maria Grazia, Galimberti, S, Devidas, M, Lucenti, A, Cazzaniga, G, Möricke, A, Bartram, C, Mann, G, Carroll, W, Winick, N, Borowitz, M, Wood, B, Basso, G, Conter, V, Zimmermann, M, Suciu, S, Biondi, A, Schrappe, M, Hunger, S, Valsecchi, M, Galimberti, Stefania, Devidas, Meenakshi, Lucenti, Ausiliatrice, Cazzaniga, Giovanni, Möricke, Anja, Bartram, Claus R, Mann, Georg, Carroll, William, Winick, Naomi, Borowitz, Michael, Wood, Brent, Basso, Giuseppe, Conter, Valentino, Zimmermann, Martin, Suciu, Stefan, Biondi, Andrea, Schrappe, Martin, Hunger, Stephen P, and Valsecchi, Maria Grazia
- Abstract
Background: The aim of this study was to assess whether minimal residual disease (MRD) at the end of induction front-line treatment can serve as a surrogate endpoint for event-free survival (EFS) in childhood B-lineage acute lymphoblastic leukemia. Methods: The analysis was based on individual data of 4830 patients from two large phase III trials that asked a randomized question on the effect of different corticosteroids (dexamethasone vs prednisone) during induction chemotherapy on EFS. The association between MRD classified in three ordered categories (negative = 0, low positive = (>0 and <5 x 10(-4)), and positive = (>= 5 x 10(-4)] and EFS at the individual and trial levels was evaluated with the meta-analytic approach based on the Plackett copula model. Centers within trial were grouped according to geographical area, and a total of 28 units were identified for the analysis. Results: MRD at the end of induction was a poor surrogate for treatment effect on EFS at the trial level, with R-trial(2) = 0.09 (95% confidence interval [CI] = 0.00 to 0.29), whereas at the individual level it was strongly associated with EFS, with an odds ratio of 3.90 (95% CI = 3.35 to 4.44) of failure for patients with higher compared with lower MRD levels. Additional sensitivity and relevant subgroup analyses confirmed these findings at both trial- and patient-level association.Conclusions: Although MRD is a robust biomarker highly predictive of outcome for individual patients, clinicians and regulatory bodies should be cautious in using early MRD response in the context of complex multiagent acute lymphoblastic leukemia therapy as an early surrogate endpoint to predict the effect of a randomized treatment intervention on long-term EFS
- Published
- 2018
42. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group
- Author
-
Salzer, WL, Jones, TL, Devidas, M, Dreyer, ZE, Gore, L, Winick, NJ, Sung, L, Raetz, E, Loh, ML, Wang, CY, de Lorenzo, P, Valsecchi, MG, Pieters, Rob, Carroll, WL, Hunger, SP, Hilden, JM, Brown, P, Salzer, W, Jones, T, Devidas, M, Dreyer, Z, Gore, L, Winick, N, Sung, L, Raetz, E, Loh, M, Wang, C, De Lorenzo, P, Valsecchi, M, Pieters, R, Carroll, W, Hunger, S, Hilden, J, Brown, P, and Pediatrics
- Subjects
Male ,Infant, Newborn ,Infant ,Induction Chemotherapy ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Article ,Infant acute lymphoblastic leukemia ,Cohort Studies ,Case-Control Studies ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Mortality ,Gram-Positive Bacterial Infections - Abstract
Background: Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis. Intensification of therapy has resulted in fewer relapses but increased early deaths, resulting in failure to improve survival. Procedure: AALL0631 is a Phase 3 study for infants (
- Published
- 2015
43. Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group (COG)
- Author
-
Gupta, S, primary, Devidas, M, additional, Loh, M L, additional, Raetz, E A, additional, Chen, S, additional, Wang, C, additional, Brown, P, additional, Carroll, A J, additional, Heerema, N A, additional, Gastier-Foster, J M, additional, Dunsmore, K P, additional, Larsen, E C, additional, Maloney, K W, additional, Mattano, L A, additional, Winter, S S, additional, Winick, N J, additional, Carroll, W L, additional, Hunger, S P, additional, Borowitz, M, additional, and Wood, B L, additional
- Published
- 2017
- Full Text
- View/download PDF
44. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children
- Author
-
Yetgin, S, Olcay, L, Dibar, E, Conter, V, Masera, G, Valsecchi, MG, Dacou-Voutetakis, C, Henze, I, Loening, L, Schrappe, M, von Stackelberg, A, Zimmermann, M, Attarbaschi, A, Gadner, H, Mann, G, Brandalise, SR, Carroll, W, Devidas, M, Gaynon, P, Hunger, S, Nachman, J, Janka, G, Stary, J, Gelber, R, and Bierings, M
- Published
- 2016
45. HTA decision-making for drugs for rare diseases: comparison of processes across countries
- Author
-
Tania Stafinski, Judith Glennie, Andrea Young, and Devidas Menon
- Subjects
Orphan drugs ,Drugs for rare diseases ,Health technology assessment ,Reimbursement processes ,International comparison ,Canada ,Medicine - Abstract
Abstract Introduction Drugs for rare diseases (DRDs) offer important health benefits, but challenge traditional health technology assessment, reimbursement, and pricing processes due to limited effectiveness evidence. Recently, modified processes to address these challenges while improving patient access have been proposed in Canada. This review examined processes in 12 jurisdictions to develop recommendations for consideration during formal government-led multi-sectoral discussions currently taking place in Canada. Methods (i) A scoping review of DRD reimbursement processes, (ii) key informant interviews, (iii) a case study of evaluations for and the reimbursement status of a set of 7 DRDs, and (iv) a virtual, multi-stakeholder consultation retreat were conducted. Results Only NHS England has a process specifically for DRDs, while Italy, Scotland, and Australia have modified processes for eligible DRDs. Almost all consider economic evaluations, budget impact analyses, and patient-reported outcomes; but less than half accept surrogate measures. Disease severity, lack of alternatives, therapeutic value, quality of evidence, and value for money are factors used in all decision-making process; only NICE England uses a cost-effectiveness threshold. Budget impact is considered in all jurisdictions except Sweden. In Italy, France, Germany, Spain, and the United Kingdom, specific factors are considered for DRDs. However, in all jurisdictions opportunities for clinician/patient input are the same as those for other drugs. Of the 7 DRDs included in the case study, the number that received a positive reimbursement recommendation was highest in Germany and France, followed by Spain and Italy. No relationship between recommendation type and specific elements of the pricing and reimbursement process was found. Conclusions Based on the collective findings from all components of the project, seven recommendations for possible action in Canada are proposed. These focus on defining “appropriate access”, determining when a “full” HTA may not be needed, improving coordination among stakeholder groups, developing a Canadian framework for Managed Access Plans, creating a pan-Canadian DRD/rare disease data infrastructure, genuine and continued engagement of patient groups and clinicians, and further research on different decision and financing options, including MAPs.
- Published
- 2022
- Full Text
- View/download PDF
46. Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy
- Author
-
Liu, Y, primary, Fernandez, CA, additional, Smith, C, additional, Yang, W, additional, Cheng, C, additional, Panetta, JC, additional, Kornegay, N, additional, Liu, C, additional, Ramsey, LB, additional, Karol, SE, additional, Janke, LJ, additional, Larsen, EC, additional, Winick, N, additional, Carroll, WL, additional, Loh, ML, additional, Raetz, EA, additional, Hunger, SP, additional, Devidas, M, additional, Yang, JJ, additional, Mullighan, CG, additional, Zhang, J, additional, Evans, WE, additional, Jeha, S, additional, Pui, C-H, additional, and Relling, MV, additional
- Published
- 2017
- Full Text
- View/download PDF
47. The Impact of Secure Messaging in the Treatment of Patients With Diabetes Within a Primary Care Setting: Protocol for a Scoping Review
- Author
-
Abdul Lawal, Devidas Menon, Ewan Affleck, and Tania Stafinski
- Subjects
Medicine ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
BackgroundDiabetes—a high-burden chronic disease—requires lifetime active management involving the use of different tools and health care resources to improve patient health outcomes. Recent studies have demonstrated promising results regarding the impact of the use of virtual care technology on the treatment of chronic diseases, such as diabetes. However, it is unclear whether the use of technologies, such as secure messaging, improves the quality of care and reduces diabetes-related costs to the health care system. ObjectiveThe purpose of our scoping review is to explore what is known about the use of secure messaging in the treatment of diabetes within the primary care setting and how its impact has been assessed from the patient and health system perspectives. Our review aims to understand to what extent secure messaging improves the quality of diabetes care. MethodsOur scoping review will follow the 6-step Arksey and O’Malley methodological framework, as well as the Joanna Briggs Institute methodology for scoping reviews and their recommended tools. The tools to guide the development and reporting of the review in a structured way will include the Population, Concept, and Context framework and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines and checklist. The search strategy was developed iteratively in collaboration with a professional information specialist. Furthermore, a peer review of electronic search strategies was also conducted by an independent, third-party, professional information specialist. A systematic literature search will be conducted against databases, including Ovid MEDLINE ALL, Embase, APA PsycINFO, Cochrane Library on Wiley, CINAHL on EBSCO, and PubMed. Grey literature sources will also be searched for relevant literature. Literature on the use of secure messaging in the treatment of diabetes (types 1 and 2) within a primary care setting will be included. Two reviewers will review the literature based on the inclusion criteria in the following two steps: (1) title and abstract review and (2) full-text review. Discrepancies will be discussed to reach consensus where possible; otherwise, a third reviewer will resolve the dispute. ResultsThe results and a final report are expected to be completed and submitted to a peer-reviewed journal in 6 months. ConclusionsThe review will examine existing literature to identify the impact of secure messaging in diabetes treatment within primary care settings. Research gaps will also be identified to determine if there is a need for further studies. International Registered Report Identifier (IRRID)DERR1-10.2196/42339
- Published
- 2023
- Full Text
- View/download PDF
48. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia
- Author
-
Richards, S, Pui, C, Gayon, P, Yetgin, Z, Olcay, L, Masera, G, VALSECCHI, MARIA GRAZIA, Schrappe, M, Zimmermann, M, Henze, G, von Stackelberg, A, Gadner, H, Mann, G, Attarbarschi, A, Brandalise, SR, Carroll, WL, Gaynon, P, Boyett, JM, Sather, HN, Devidas, M, Escheriche, G, Gelber, RD, Sallan, SE, Pieters, R, Bierings, M, Kamps, WA, Otten, J, Suciu, S, Viana, MB, Stark, B, Steinberg, D, Koizumi, S, Tsurusawa, M, Eden, OB, Mitchell, C, Steinherz, PG, Ortega, JJ, Nachman, J, Appelbaum, FR, Cheng, C, Pei, D, Pui, CH, Clarke, M, Elphinstone, P, Evans, V, Gregory, C, Gettins, L, Hicks, C, James, S, MacKinnon, L, McHugh, TM, Morris, P, Wade, R., Richards, S, Pui, C, Gayon, P, Yetgin, Z, Olcay, L, Masera, G, Valsecchi, M, Schrappe, M, Zimmermann, M, Henze, G, von Stackelberg, A, Gadner, H, Mann, G, Attarbarschi, A, Brandalise, S, Carroll, W, Gaynon, P, Boyett, J, Sather, H, Devidas, M, Escheriche, G, Gelber, R, Sallan, S, Pieters, R, Bierings, M, Kamps, W, Otten, J, Suciu, S, Viana, M, Stark, B, Steinberg, D, Koizumi, S, Tsurusawa, M, Eden, O, Mitchell, C, Steinherz, P, Ortega, J, Nachman, J, Appelbaum, F, Cheng, C, Pei, D, Clarke, M, Elphinstone, P, Evans, V, Gregory, C, Gettins, L, Hicks, C, James, S, Mackinnon, L, Mchugh, T, Morris, P, and Wade, R
- Subjects
Central Nervous System Neoplasms ,Antineoplastic Agent ,Central Nervous System ,Central Nervous System Neoplasm ,Humans ,Antineoplastic Agents ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Child ,Article ,Injections, Spinal ,Randomized Controlled Trials as Topic ,Human - Abstract
Treatment of the central nervous system (CNS) is an essential therapy component for childhood acute lymphoblastic leukemia (ALL). Individual patient data from 47 trials addressing 16 CNS treatment comparisons were analyzed. Event-free survival (EFS) was similar for radiotherapy versus intrathecal (IT), and radiotherapy plus IT versus IV methotrexate (IV MTX) plus IT. Triple intrathecal therapy (TIT) gave similar EFS but poorer survival than intrathecal methotrexate (IT MTX), but additional IV MTX improved both outcomes. One trial resulted in similar EFS and survival with IV MTX plus IT MTX versus TIT alone. Radiotherapy can generally be replaced by IT therapy. TIT should be used with effective systemic therapy such as IV MTX.
- Published
- 2013
49. Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review
- Author
-
Fernanda Inagaki Nagase, Tania Stafinski, Melita Avdagovska, Michael K. Stickland, Evelyn Melita Etruw, and Devidas Menon
- Subjects
COPD ,Remote monitoring ,Home-based ,Systematic review ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Although remote home monitoring (RHM) has the capacity to prevent exacerbations in patients with chronic obstructive pulmonary disease (COPD), evidence regarding its effectiveness remains unclear. The objective of this study was to determine the effectiveness of RHM in patients with COPD. Methods A systematic review of the scholarly literature published within the last 10 years was conducted using internationally recognized guidelines. Search strategies were applied to several electronic databases and clinical trial registries through March 2020 to identify studies comparing RHM to ‘no remote home monitoring’ (no RHM) or comparing RHM with provider’s feedback to RHM without feedback. To critically appraise the included randomized studies, the Cochrane Collaboration risk of bias tool (ROB) was used. The quality of included non-randomized interventional and comparative observational studies was evaluated using the ACROBAT-NRSI tool from the Cochrane Collaboration. The quality of evidence relating to key outcomes was assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) on the following: health-related quality of life (HRQoL), patient experience and number of exacerbations, number of emergency room (ER) visits, COPD-related hospital admissions, and adherence as the proportion of patients who completed the study. Three independent reviewers assessed methodologic quality and reviewed the studies. Results Seventeen randomized controlled trials (RCTs) and two comparative observational studies were included in the review. The primary finding of this systematic review is that a considerable amount of evidence relating to the efficacy/effectiveness of RHM exists, but its quality is low. Although RHM is safe, it does not appear to improve HRQoL (regardless of the type of RHM), lung function or self-efficacy, or to reduce depression, anxiety, or healthcare resource utilization. The inclusion of regular feedback from providers may reduce COPD-related hospital admissions. Though adherence RHM remains unclear, both patient and provider satisfaction were high with the intervention. Conclusions Although a considerable amount of evidence to the effectiveness of RHM exists, due to heterogeneity of care settings and the low-quality evidence, they should be interpreted with caution.
- Published
- 2022
- Full Text
- View/download PDF
50. Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review
- Author
-
Tania Stafinski, Fernanda Inagaki Nagase, Melita Avdagovska, Michael K. Stickland, and Devidas Menon
- Subjects
COPD ,Pulmonary rehabilitation ,Home-based ,Systematic review ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Although pulmonary rehabilitation (PR) is considered a key component in managing chronic obstructive pulmonary disease (COPD) patients, uptake remains suboptimal. This systematic review aimed to determine the effectiveness of home-based PR (HBPR) programs for COPD patients. Methods A systematic review of scholarly literature published within the last 10 years from the conception of this project was conducted using internationally recognized guidelines. Search strategies were applied to electronic databases and clinical trial registries through March 2020 and updated in November 2021 to identify studies comparing HBPR with ‘usual care’ or outpatient pulmonary rehabilitation (OPR). To critically appraise randomized studies, the Cochrane Collaboration risk of bias tool (ROB) was used. The quality of non-randomized studies was evaluated using the ACROBAT-NRSI tool. The quality of evidence relating to key outcomes was assessed using Grading of Recommendations, Assessment, Development and Evaluations (GRADE) on health-related quality of life (HRQoL), exacerbation frequencies, COPD-related hospital admissions, and program adherence. Three independent reviewers assessed methodologic quality and reviewed the studies. Results Twelve randomized controlled trials (RCTs) and 2 comparative observational studies were included. While considerable evidence relating to the effectiveness of HBPR programs for COPD patients exist, overall quality is low. There were no differences between HBPR and OPR in terms of safety, HRQoL, functional exercise capacity and health care resource utilization. Compared to usual care, functional exercise capacity seemed to significantly improve after HBPR. While patient compliance with HBPR is good, two factors appeared to increase the ‘risk’ of non-compliance: expectations of patients to 1) complete daily diaries/activity logs and 2) engage in solely unsupervised exercise sessions. Conclusion The overall quality for most outcomes was low to very low; however, HBPR seems to offer comparable short-term benefits to OPR.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.